Not an actual patient.
Based on the initial diagnosis assessment or if the prostate cancer has come back (also known as a recurrence), it’s important to know if and where the prostate cancer has spread—or metastasized. That’s where imaging comes in. It can play a vital role in helping to detect and monitor prostate cancer progression. However, not all imaging scans are the same. While many of the current options—such as bone, CT, and MRI scans—provide some important information, they also have limitations.
PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.